• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA green-lights expansion of HeartWare’s Advance trial

FDA green-lights expansion of HeartWare’s Advance trial

April 8, 2010 By MassDevice staff

HTWR logo

The Food & Drug Administration approved a bid by HeartWare International Inc. (NSDQ:HTWR) to expand the Advance trial examining its ventricular assist device as a bridge to transplant in patients with end-stage heart failure.

The FDA granted an investigational device exemption supplement to allow the Framingham, Mass.-based firm to expand the trial by 54 patients. The study, aimed at evaluating the device’s suitability in patients who are waiting for a heart transplant, will measure survival rates after 180 days, the incidence of adverse events such as bleeding and infection, functional status, hospitalization, neuro-cognitive function and quality of life.

So far, 140 patients at 30 sites have been implanted with the HVAD device, a small implantable pump designed to assist the heart’s ventricles in pumping blood. The last of those subjects is expected to reach the 180-day mark by the end of August. The FDA nod means HeartWare can now begin enrolling the additional patients under a modified protocol, setting the company up for a possible pre-market approval application in December.

In October 2008, HeartWare won approval to expand the Advance study from 28 to 40 sites; at the time, 22 clinics were participating in the trial. Last month the ahead-of-schedule enrollment of the 140th patient triggered milestone bonuses for HeartWare executives, under performance rights plans adopted by the HeartWare board in 2007 and 2008. The executives received restricted stock awards worth between $100,000 and nearly $1.3 million, depending on their position on the corporate ladder.

The company closed 2009 on a high note, with soaring sales and slashed losses. HeartWare posted sales of $12.2 million during the three months ended Dec. 31, 2009, up a whopping 4,900 percent compared with $244,000 during the same period in 2009. Fourth-quarter net losses plunged 51.4 percent, to $1.9 million (or 176 cents per share) compared with $3.9 million (44 cents per share) during Q4 2008.

HeartWare’s top line fared even better during the full year, soaring 7,180 percent to $24.2 million compared with $332,000 in 2008. Annual net losses were down 12 percent to $20.9 million ($2.15 per share) in 2009, compared with $23.8 million ($3.00 per share) during the prior year.

And early in February the company pulled in $62.8 million from a public stock offering, selling nearly 1.8 millions shares for a net gain of $59 million.

Filed Under: Business/Financial News, News Well, Structural Heart Tagged With: HeartWare International Inc.

More recent news

  • Data backs DermaSensor skin cancer detection device
  • GE HealthCare expands digital imaging portfolio with enhanced MIM Encore software
  • Accelus wins FDA clearance for MRI compatibility of FlareHawk spinal implants
  • Presidio wins FDA IDE for ultra-low frequency neuromod, hires new CFO
  • Epiminder study backs implantable EEG tech

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy